VolitionRx reports Q1 revenue $1M, consensus $409,920

Cameron Reynolds, President and Group Chief Executive Officer, said: “We have made strong progress across all of our product pillars during the first quarter and indeed subsequent to quarter end. We announced the submission for peer review of a clinical manuscript reporting the high accuracy of our Nu.Q Vet feline prototype assay in detecting lymphoma in cats, our third species. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5 million contractual milestone payment. The feline test could greatly expand the market of our Nu.Q Vet platform.”